These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 9379142)

  • 21. Bidirectional interactions of NK cells and dendritic cells in immunotherapy: current and future perspective.
    Mahmood S; Upreti D; Sow I; Amari A; Nandagopal S; Kung SK
    Immunotherapy; 2015; 7(3):301-8. PubMed ID: 25804481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.
    Ishida A; Tanaka H; Hiura T; Miura S; Watanabe S; Matsuyama K; Kuriyama H; Tanaka J; Kagamu H; Gejyo F; Yoshizawa H
    Scand J Immunol; 2007 Nov; 66(5):546-54. PubMed ID: 17953530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular immunotherapy with dendritic cells in cancer: current status.
    Nencioni A; Brossart P
    Stem Cells; 2004; 22(4):501-13. PubMed ID: 15277696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy with dendritic cells for cancer.
    Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
    Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innate immune cells for immunotherapy of autoimmune and cancer disorders.
    Schäfer C; Ascui G; Ribeiro CH; López M; Prados-Rosales R; González PA; Bueno SM; Riedel CA; Baena A; Kalergis AM; Carreño LJ
    Int Rev Immunol; 2017 Nov; 36(6):315-337. PubMed ID: 28933579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic-cell-based therapeutic cancer vaccines.
    Palucka K; Banchereau J
    Immunity; 2013 Jul; 39(1):38-48. PubMed ID: 23890062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for immunotherapy of cancer.
    Melief CJ; Toes RE; Medema JP; van der Burg SH; Ossendorp F; Offringa R
    Adv Immunol; 2000; 75():235-82. PubMed ID: 10879286
    [No Abstract]   [Full Text] [Related]  

  • 28. Promise of cancer stem cell vaccine.
    Zhou L; Lu L; Wicha MS; Chang AE; Xia JC; Ren X; Li Q
    Hum Vaccin Immunother; 2015; 11(12):2796-9. PubMed ID: 26337078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell vaccination for cancer therapy.
    Nestle FO
    Oncogene; 2000 Dec; 19(56):6673-9. PubMed ID: 11426654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
    He T; Tang C; Xu S; Moyana T; Xiang J
    Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy.
    Cho NH; Cheong TC; Min JH; Wu JH; Lee SJ; Kim D; Yang JS; Kim S; Kim YK; Seong SY
    Nat Nanotechnol; 2011 Sep; 6(10):675-82. PubMed ID: 21909083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunity and immunosuppression in tumor growth].
    Govallo VI
    Vopr Onkol; 1987; 33(4):91-9. PubMed ID: 3296437
    [No Abstract]   [Full Text] [Related]  

  • 33. Nanomedicine for improvement of dendritic cell-based cancer immunotherapy.
    Hashemi V; Farhadi S; Ghasemi Chaleshtari M; Seashore-Ludlow B; Masjedi A; Hojjat-Farsangi M; Namdar A; Ajjoolabady A; Mohammadi H; Ghalamfarsa G; Jadidi-Niaragh F
    Int Immunopharmacol; 2020 Jun; 83():106446. PubMed ID: 32244048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Applications of gene transfer to cellular immunotherapy.
    Terando A; Chang AE
    Surg Oncol Clin N Am; 2002 Jul; 11(3):621-43. PubMed ID: 12487059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive immunotherapy.
    Ballen K; Stewart FM
    Curr Opin Oncol; 1997 Nov; 9(6):579-83. PubMed ID: 9370080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer.
    Gabrilovich DI; Cunningham HT; Carbone DP
    J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):414-8. PubMed ID: 9041460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular immunotherapy of cancer: an overview and future directions.
    Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
    Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cells: a journey from laboratory to clinic.
    Cerundolo V; Hermans IF; Salio M
    Nat Immunol; 2004 Jan; 5(1):7-10. PubMed ID: 14699398
    [No Abstract]   [Full Text] [Related]  

  • 39. Harnessing human plasmacytoid dendritic cells as professional APCs.
    Tel J; van der Leun AM; Figdor CG; Torensma R; de Vries IJ
    Cancer Immunol Immunother; 2012 Aug; 61(8):1279-88. PubMed ID: 22294456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoptive transfer of naïve dendritic cells in resolving post-sepsis long-term immunosuppression.
    Laudanski K
    Med Hypotheses; 2012 Oct; 79(4):478-80. PubMed ID: 22840328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.